JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the second quarter ended June 30, 2007. Second Quarter Highlights * Record-breaking quarterly net sales of $2,386 million, up 10 percent over the second quarter of 2006—a quarter which included the launches with exclusivity of Simvastatin and Pravastatin, among the largest launches in the industry’s history.
